Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference
November 22, 2021 16:53 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient...
Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics’ INT230-6 (PORT-1) at November Scientific Conferences
November 15, 2021 08:00 ET
|
Portage Biotech, Inc.
Data presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Connective Tissue Oncology Society (CTOS) Annual Meeting suggest INT230-6 (PORT-1) offers a promising approach...
Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology Treatment
November 10, 2021 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient...
Portage Biotech Announces Participation in September 2021 Investor Conferences
September 10, 2021 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies...
Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year
August 30, 2021 08:00 ET
|
Portage Biotech, Inc.
- $29 million raised during quarter with broad institutional support - Proceeds will accelerate advancement of clinical pipeline toward multiple data readouts over the next 18-24 months WESTPORT,...
Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)
August 05, 2021 08:00 ET
|
Portage Biotech, Inc.
Novel iNKT agonist leads to a broad reprogramming of the innate and adaptive immune system to target cancerPORT-2 has the potential to re-sensitize checkpoint-resistant tumors to treatment with PD-1...